The Royal Pharmaceutical Society (RPS) Director for Scotland, Clare Morrison will be joining NHS Scotland in January.
Morrison has been appointed Director of Community Engagement at Healthcare Improvement Scotland.
Paul Bennett, RPS CEO said: "Many people, particularly in Scotland, will know of Clare's passion for quality improvement and patient involvement in the co-design
of services. This was demonstrated through her previous work on the development of Near Me, NHS Scotland's video consulting service, and its co-design with the
public, patients, clinicians and NHS staff which gained international recognition from the Institute for Healthcare Improvement.
"Therefore, this is an exciting opportunity for Clare to join Healthcare Improvement Scotland to take on a strategic leadership role in supporting effective community
engagement across health and social care in Scotland. It also enables Clare to make even greater use of her training as an NHS Scotland Scottish Quality & Safety
Fellow and we wish her every success in her new role.
RPS Scotland has named Fiona McIntyre as its new Policy and Practice Lead. With a background in hospital pharmacy, McIntyre will be responsible for policy
development and professional support at RPS Scotland, and is set to assume her new role in early October.
McIntyre will assume a leadership role for specific projects across Great Britain, collaborating with the Policy and Practice Leads in England and Wales, RPS
Scotland said in a statement. Her responsibilities include representing pharmacists in working groups and meetings, engaging with pharmacists and pharmacy
organisations, and supporting the RPS Director for Scotland.
"During my career in NHS Scotland, I have advocated for pharmacy teams whenever possible," said McIntyre. "I am passionate about the profession's role in the
safe and effective use of medicines, and I'm privileged to join the RPS. I look forward to promoting pharmacy in Scotland and helping our profession reach its
full potential."
"I'm pleased that Fiona will be joining the RPS Scotland team as our policy lead," said Laura Wilson, Director for RPS Scotland. "Fiona's experience will be
invaluable to the role, and the whole team looks forward to her starting with us in October."
The Royal Pharmaceutical Society (RPS) has appointed Laura Wilson as Director for Scotland commencing 23rd January 2023.
Laura, is currently Policy and Practice Lead for RPS in Scotland. She is accountable for bringing national RPS policy to life for members in Scotland, while
contributing to the GB wide professional leadership agenda.
She will work closely with the Scottish Pharmacy Board, senior NHS officials and other key stakeholders across the breadth of the pharmacy profession and beyond
to ensure pharmacy is on the forefront of healthcare in Scotland.
She joins the existing team of RPS Country Directors, which includes Elen Jones, Director for Wales and James Davies, Director for England and will report directly
to the Chief Executive.
Laura Wilson said: "I am delighted to be appointed Director for Scotland having worked as part of the RPS Scotland team as the policy and practice lead. It will
be an honour to continue the fantastic work started by former Director Clare Morrison to bring Pharmacy 2030, our vision for pharmacy in Scotland in the future,
to life and supporting pharmacy teams to deliver person centred care.
Royal Pharmaceutical Society (RPS) and the Royal College of General Practitioners in Scotland hosted an event celebrating the collaborative work of the health
professions and policy makers in Scotland on reducing the environmental harm from prescribing and medicines use.
To share priorities for the Scottish Government, Alpana Mair, Head of Effective Therapeutics and Prescribing spoke and National Clinical Director Jason Leitch
appeared virtually. Gillian MacKay MSP, Scottish Greens spokesperson for Health and Social Care also joined in-person.
Medicines account for around 25% of the NHS's carbon emissions and have an ecological impact when they enter our wastewater system or our rivers and oceans.
Tackling the impact of prescribing will be a key part of meeting the ambition of a net zero NHS Scotland by 2040 at the latest.
Together, RCGP Scotland and RPS have held two roundtable events on sustainable prescribing, and in June 2022, released a joint statement calling for a wide range
of actions, which was signed by the Academy of Medical Royal Colleges and Faculties in Scotland, the Royal College of Physicians of Edinburgh, the Royal College of
Anaesthetists, the College of Radiographers, Royal College of Nursing, Queen's Nursing Institute Scotland and Chartered Society of Physiotherapy.
Continuing the work of RPS at the International Forum on Quality and Safety in Healthcare, the event aims to mark an opportunity for health professionals and
decision makers alike to join a global movement of sustainability in healthcare, and pledge to continue the important work of cutting the climate impact of medicine
use while maintaining the highest level of patient care and safety.
The Royal Pharmaceutical Society (RPS) has welcomed the appointment of Michael Matheson MSP as Cabinet Secretary for NHS Recovery, Health and Social Care in
Scotland.
Commenting on the announcement Laura Wilson, Director of RPS Scotland, said: "I would like to congratulate Michael Matheson on being appointed to this position.
NHS recovery is vitally important, and pharmacy has a huge amount to offer this agenda.
"Our current priorities include enabling pharmacists to take leadership of prescribing in all care settings, tackling health inequalities and advocating for change,
implementing shared patient records between healthcare professionals to provide high-quality, person centred and safe patient care, improving pharmacists' wellbeing
and tackling the climate emergency by encouraging sustainable and green prescribing across Scotland.
"Discussions must involve the government on behalf of NHS Scotland, CPS on behalf of the owners, and the PDA as the pharmacists' representative," it said.
The association believes that there is a need for discussion and decision-making that listens to and balances the rights and responsibilities of both employers
and workers, to generate benefits for individuals, organisations, and society.
It added: "Even though Scotland provides the most generous community pharmacy settlement in the UK, recent reports suggest it is not enough for pharmacy owners
with CPS's rejection of the latest funding proposal in May. Though the Scottish government found an extra £20M to ease pressures related to medicines price
increases, an overall agreement has still not been reached."
"The UK-wide chains may be doing less well in the parts of their networks covered by the Westminster government's contract, but the taxpayers and government of
Scotland need to be given reassurance that they are in no way subsidising funding shortfalls in England's pharmacy contract."
Recently, when LloydsPharmacy's Scotland branches recently came on the market, they appear to have been sold exclusively to existing contractors, including the
UK-wide multiple, Rowlands Pharmacy, who have acquired 30 of them. Other small and medium-sized Scottish pharmacy chains have apparently been able to double in
size overnight by acquiring branches.
The NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) has published a report that demonstrated the importance of the
collaboration between industry and the NHS to improve patient outcomes across the UK.
Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments
in these areas continues to be below the average of similar countries in Europe.
The report, 'Transforming Lives, Improving Health Outcomes', has highlighted four initiatives where effective partnerships between the NHS, patient organisations
and industry have helped to tackle unwarranted variation in the uptake of innovative medicines.
Transforming Lives, Improving Health Outcomes also called for a systemwide secondary prevention strategy covering all parts of the health system creating a barrier
to wider and consistent uptake of innovative medicine. It also noted that newly created Integrated Care Systems have the potential to improve preventative treatment.
The report data also showed a 51% variation of uptake of three types of medicines related to diabetes between NHS Trusts in England.
NHS Greater Glasgow and Clyde has appointed Jennifer Laskey as Scotland's first consultant pharmacist, marking a significant step forward for pharmacy
profession in the country.
Laskey's new role involves providing support to the West of Scotland Cancer Network, where she will play a pivotal role in enhancing healthcare outcomes.
Her appointment underscores the commitment of NHS Greater Glasgow and Clyde to improving patient care and highlights the growing importance of pharmacist-led
initiatives in Scotland's healthcare landscape.
Laskey, a pharmacist from Scotland, will extend her expertise to bolster the West of Scotland Cancer Network, aiming to enhance outcomes and survival rates
across various healthcare settings.
As part of recruitment to become a consultant pharmacist, Laskey obtained credentials from the RPS serving in an accredited consultant post ensuring
standardisation across the UK for patients and the system.
Recently, the English Health Secretary has talked about introducing a 'Pharmacy First' model similar to that which exists in Scotland. This would be a win-win
outcome providing people with better access to essential healthcare support, advice and treatment whilst relieving strain on other parts of the NHS, not least GPs
and A&E.
It is a no-brainer and yet despite a few media headlines there are still no firm proposals on the table to make this a reality. It surely cannot be right that you
can receive a broad range of patient care services in Scotland which are not available in England. It works well in Scotland, Wales is keen to develop more
pharmacy-based services and Northern Ireland, leaving aside the current funding dispute, has had a minor ailments service for many years.
If the English Health Secretary is sincere in his interest in adopting an English version of the Scottish model, then there are critical aspects he needs to
consider.
Firstly, start with the patient journey through the healthcare ecosystem from illness prevention through to long-term condition management. What is the role of
community pharmacy and how do we guide people to seek support from the most appropriate healthcare professional?
What is the vision for community pharmacy delivering patient care in the next decade?
The lesson from Scotland is that the government needs to sit down with the sector and map that out together. There are no quick fix overnight solutions. This needs
to be a long-term commitment backed by adequate funding. Supervision regulations need to change and there needs to be a thought through workforce strategy which
avoids community pharmacy shortages as that does nothing to deliver improved patient outcomes.
Representatives for prescribers across Scotland, politicians, academics and clinicians gathered to discuss the importance of environmental sustainability
in healthcare during a Scottish Parliamentary reception held at Holyrood on Wednesday (13 December).
Royal Pharmaceutical Society (RPS) informed the parliament that medicines account for around 25 per cent of carbon emissions across the NHS, while highlighting
the various innovative ways to reduce these carbon emissions.
The NHS in Scotland needs to implement effective environmentally sustainable approaches to healthcare in order to meet its ambition to achieve net zero, RPS
pointed out.
Laura Wilson, Director for Scotland at RPS, said: "It was fantastic to bring together pharmacists, parliamentarians and partners from across government and
healthcare to highlight the huge opportunity which exists in healthcare to make our systems and processes more environmentally sustainable.
Three leading healthcare bodies in Scotland have called for action to reduce the environmental impact caused by medicine prescribing.
The Academy of Medical Royal Colleges and Faculties in Scotland, Royal Pharmaceutical Society and the Royal College of General Practitioners Scotland have all
urged policymakers to enable a more sustainable approach to prescribing.
This includes prioritising the introduction of electronic prescribing across the NHS, introducing the requirement for an environmental impact in NHS medicines
procurement and improving the availability of data about the environmental impact of medicines.
"We call on Scottish government, including the chief medical officer, to enable the delivery of a realistic medicine approach to prescribing by developing a
supportive infrastructure for green social prescribing across Scotland," said the healthcare professionals in a joint statement.
They have called on the pharmaceutical industry to make information about the environmental impact of medicines readily available in a standardised data format.
The community pharmacy staff in Scotland will not be required to work for a minimum of five full days if they test positive for Covid-19.
The Scottish health secretary Humza Yousaf has clarified that health and social care employees, including community pharmacists, will have to follow the guidance
on managing staff with symptoms of a respiratory infection, or a positive Covid-19 test.
While responding to Jackie Baillie (Dumbarton) (Scottish Labour Party) written parliamentary question, Humza said, "If they work with patients or service users in
face-to-face settings, they can return to work if they have had two consecutive negative LFD test results (taken at least 24 hours apart)."
Jackie asked the Scottish government, "what its position is on the actions of Well Pharmacy, in light of reports that the company is insisting that staff who test
positive for COVID-19 continue to work when they are in patient-facing roles and dealing with clinically vulnerable people?"
The Pharmacists' Defence Association said: "This means that Well pharmacy will have to change their policy in Scotland and no longer allow Covid positive staff to
work in their pharmacies."
The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years.
Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book.
Besides, children living with someone immunosuppressed will be eligible to get the first dose of the Covid vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI).
According to the NHS there are around 500,000 eligible children in the latest cohort.
GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.
The Scottish Government and Community Pharmacy Scotland have agreed to roll out next month a new national service to provide emergency access to supplies
of naloxone.
An NHS circular signed by Alison Strath, Chief Pharmaceutical Officer of Scotland, advises that the emergency supply service will be added to the community
pharmacy Public Health Service from 30 October 2023. It states that community pharmacy contractors and pharmacy teams should ensure they are familiar with the
new arrangements.
Community pharmacy contractors have been asked to ensure that pharmacy teams complete the e-learning module for naloxone emergency supply. They are also encouraged
to join webinars to support the implementation of the service which will be held on Wednesday 4 October and Tuesday 14 November at 19:30. Details of how to register
can be found at on NHS Scotland's Turas platform.
The Department of Health and Social Care (DHSC) launched a new Innovative Medicines Fund on Tuesday (June 7) under which £340 million has been made available
to purchase potentially life-saving drugs early.
This will allow NHS patients in England to have early access to potentially life-saving and cutting-edge treatments
Health secretary Sajid Javid said: "I want NHS patients to be the first in the world to access the most promising and revolutionary treatments that could extend or
save their lives.
"The launch of the Innovative Medicines Fund delivers another manifesto pledge and will fast-track cutting-edge medicines to adults and children to give people
renewed hope for a better future."
A total of £680 million has been ringfenced for the Innovative Medicines Fund and Cancer Drugs Fund - £340 million each - to fast-track medicines to NHS patients.
DHSC said: "The Innovative Medicines Fund will provide quick access to novel treatments, including potentially lifesaving gene therapies for serious conditions with
few treatment options. It often takes longer for pharmaceutical companies to collect data on a medicine's clinical and cost effectiveness for rare diseases due to
the smaller patient cohort.
A three-year contract has been signed between NHS Education for Scotland (NES) and Pharmaceutical Press, the Royal Pharmaceutical Society's (RPS) knowledge business, to continue the supply of trusted medicines information though MedicinesComplete, to healthcare professionals in Scotland.
The renewed investment from NES demonstrates unequivocal confidence in the publisher and highlights Pharmaceutical Press' ongoing commitment to provide practical and evidence-based guidance, supporting those who prescribe, dispense, and administer medicines. Essential resources include Martindale: The Complete Drug Reference, Palliative Care formulary, Stockley's Drug Interactions and Critical Illness.
Relied on by healthcare professionals globally for use in everyday practice, clear and concise guidance through MedicinesComplete supports confident decision-making
at the point of care.
Following discussions with Community Pharmacy Scotland, the Scottish government has agreed to a six per cent rise in the global fund allocation for community
pharmacies in 2023-24, bringing the total remuneration to approximately £219.5 million.
A finalised agreement has been reached with Community Pharmacy Scotland for a one-year funding package for the financial year 2023-24, as stated in a Scottish
government circular distributed to community pharmacy contractors and NHS Boards on August 4.
The circular said this settlement will lead to the most substantial increment ever approved for the community pharmacy network.
"The global sum remuneration will be £219.533 million, signifying a 6 per cent increase from the previous year and setting the groundwork for 2024/25," stated
Professor Alison Strath, Chief Pharmaceutical Officer for Scotland, in the document. "The guaranteed income from the drug tariff will remain at £80 million for
the financial year, without yearly changes."
The Royal Pharmaceutical Society (RPS) Scotland the BMA's Scottish GP Committee has called for improvements to the pharmacotherapy service.
The joint statement released by the organisations on Friday (13 January), has recognised that much progress has been made but states that further improvements are
needed to fully maximise the benefits of the service.
It highlighted the need for better use of skill mix, including more clearly defining roles and responsibilities; improved IT enablers to reduce administrative burden;
and further developing a tandem model of working comprising hubs with in-practice activity
The two organisations state that inadequate funding and workforce shortages are a real threat to the pharmacotherapy service.
They have urge Scottish Government to reconsider its recent decision to reduce funding for training pharmacy technicians.
Clare Morrison, RPS Director for Scotland, said: "In the statement, we stress that the use of pharmacists' clinical skills must be maximised.
The Royal Pharmaceutical Society and Scottish Academy of Medical Royal Colleges co-hosted the NHS Education for Scotland annual virtual conference to discuss
the environmental impact of prescribing.
One of the conclusions drawn from the conference on Thursday (April 28) stressed on environmentally sustainable prescribing should be embedded in undergraduate
and postgraduate health care education.
Delegates at the session said they or their teams needed more education. They also needed more information and resources when prescribing to be able to consider
environmental issues.
Sharon Pfleger, Consultant in Pharmaceutical Public Health at NHS Highland, told the session: "There's a lot of work to be done to reduce carbon emissions. The
NHS has identified the use of metered-dose inhalers as its second biggest cause of carbon emissions as the propellant gases have significant global warming potential.
The Royal Pharmaceutical Society (RPS) presented the best practice award to a pharmacist from NHS Tayside at an event on May 29 which celebrated pharmacy
practice across Scotland.
The Glasgow event, organised by RPS, brought together pharmacists from across the country to present their own best-practice examples.
These included all sectors of pharmacy, including hospital, GP practices, community and specialist settings.
Delegates at the event were asked to vote for what they considered to be the winning example of best practice. Alex Matos, specialist clinical pharmacist, won the
award for his presentation on 'Implementing Pharmacogenomics in the Stroke Service'.
Alex won a £500 bursary for travel and accommodation to the RPS's annual conference in London, where he has been invited to present on his best practice example.